Principal Investigator
Samuel McLean, MD
University of North Carollina at Chapel Hill
- 2 trials
- 2 recruiting now
- 2 compounds
Therapeutic focus
- Acute Stress Reaction
- Acute Stress Disorder
- Post-traumatic Stress Disorder
- Post-Traumatic Stress Disorder
- Neurocognitive Function
Recruiting now (2)
| NCT | Phase | Status | Compound | Sponsor |
|---|---|---|---|---|
| NCT06943404 | Phase 2 | Recruiting | Dexmedetomidine sublingual film (BXCL501) | BioXcel Therapeutics, Inc. |
| NCT06636786 | Phase 2 | Recruiting | TNX-102 SL (cyclobenzaprine HCl sublingual) | Tonix Pharmaceuticals Holding Corp. |
All trials (2)
| NCT | Phase | Status | Compound | Sponsor |
|---|---|---|---|---|
| NCT06943404 | Phase 2 | Recruiting | Dexmedetomidine sublingual film (BXCL501) | BioXcel Therapeutics, Inc. |
| NCT06636786 | Phase 2 | Recruiting | TNX-102 SL (cyclobenzaprine HCl sublingual) | Tonix Pharmaceuticals Holding Corp. |
Compounds studied
Trial sites (10)
- Indianapolis, Indiana, United States
- Charlottesville, Virginia, United States
- Columbus, Ohio, United States
- Providence, Rhode Island, United States
- Kansas City, Kansas, United States
- Birmingham, Alabama, United States
- St Louis, Missouri, United States
- Jacksonville, Florida, United States
- San Antonio, Texas, United States
- Camden, New Jersey, United States
Investigator and site data mirrored fromClinicalTrials.gov (public domain).